DreaMed DiabetesDreaMed Diabetes AI announced today that it received FDA clearance that expands its platform’s target population to cover type 1 and type 2 diabetes.

Tel Aviv, Israel-based DreaMed’s Advisor Pro AI clinical decision support system assists healthcare providers in the management of diabetes patients who use insulin pumps or injections and monitor their glucose using a continuous glucose monitor (CGM) and/or blood glucose meters.

Get the full story at our sister site, Drug Delivery Business News.